Literature DB >> 27927759

CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study.

Wim Adriaensen1,2, Graham Pawelec3,4, Bert Vaes1,2, Klaus Hamprecht5, Evelyna Derhovanessian3, Gijs van Pottelbergh6, Jean-Marie Degryse1,2, Catharina Matheï6.   

Abstract

The occurrence and general applicability of the CD4:8 ratio as a surrogate predictor of mortality among the oldest old have only been tested in a few longitudinal studies. Here, the predictive value of CD4:8 ratio for mortality with respect to the role of cytomegalovirus (CMV) infection was investigated. Using polychromatic flow cytometry, the CD4:8 ratio and T-cell subsets of 235 individuals aged 81.5 years or older were analyzed, and mortality data were collected after a mean period of 3.3 years. The hazard for all-cause mortality adjusted for age, comorbidity, and CMV serostatus increased 1.53-fold (95% CI: 0.94-2.51) with every increment in the CD4:8 ratio from R < 1, to 1 < R < 5 and R > 5 among women. A negative hazard ratio of 0.50 for CMV seropositivity in women indicated an apparently protective effect of this virus. In men, no associations with survival were observed. No mediation effect could be found for the CD4:8 ratio with respect to the relationship between CMV serostatus and mortality. Very elderly CMV-negative women with a R > 5 experienced the highest mortality rates, independent of age and comorbidity. The associations of CMV serostatus and CD4:8 ratio with mortality seem to reflect distinct pathways mediating life span in very old humans.
© The Author 2016. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Cytomegalovirus; Mortality; Oldest old; Sex differences; T-cell distribution

Mesh:

Year:  2017        PMID: 27927759     DOI: 10.1093/gerona/glw215

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  8 in total

Review 1.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Authors:  Luigi Ferrucci; Elisa Fabbri
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

2.  Age-Related Differences in T-Cell Subsets in a Nationally Representative Sample of People Older Than Age 55: Findings From the Health and Retirement Study.

Authors:  Bharat Thyagarajan; Jessica Faul; Sithara Vivek; Jung K Kim; Janko Nikolich-Žugich; David Weir; Eileen M Crimmins
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2022-05-05       Impact factor: 6.591

Review 3.  The conundrum of human immune system "senescence".

Authors:  Graham Pawelec; Anne Bronikowski; Stephen C Cunnane; Luigi Ferrucci; Claudio Franceschi; Tamas Fülöp; Pierrette Gaudreau; Vadim N Gladyshev; Efstathios S Gonos; Vera Gorbunova; Brian K Kennedy; Anis Larbi; Jean-François Lemaître; Guang-Hui Liu; Andrea B Maier; José A Morais; Otávio T Nóbrega; Alexey Moskalev; Marcel Olde Rikkert; Andrei Seluanov; Alistair M Senior; Svetlana Ukraintseva; Quentin Vanhaelen; Jacek Witkowski; Alan A Cohen
Journal:  Mech Ageing Dev       Date:  2020-09-17       Impact factor: 5.432

Review 4.  Is There a Positive Side to T Cell Exhaustion?

Authors:  Graham Pawelec
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

5.  "The ancient and the new": is there an interaction between cytomegalovirus and SARS-CoV-2 infection?

Authors:  Paul Moss
Journal:  Immun Ageing       Date:  2020-05-27       Impact factor: 6.400

6.  Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Authors:  Cecilia Söderberg-Nauclér
Journal:  Immun Ageing       Date:  2021-03-12       Impact factor: 6.400

Review 7.  Does the human immune system ever really become "senescent"?

Authors:  Graham Pawelec
Journal:  F1000Res       Date:  2017-08-04

Review 8.  The human immunosenescence phenotype: does it exist?

Authors:  Graham Pawelec
Journal:  Semin Immunopathol       Date:  2020-08-05       Impact factor: 9.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.